https://wikimd.org/index.php?action=history&feed=atom&title=VaniprevirVaniprevir - Revision history2026-04-25T11:39:00ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Vaniprevir&diff=5369030&oldid=prevPrab: CSV import2024-03-06T04:44:56Z<p>CSV import</p>
<p><b>New page</b></p><div>[[File:Vaniprevir.png|thumb|{{PAGENAME}}]]<br>'''Vaniprevir''' is a [[protease inhibitor]] used in the treatment of [[Hepatitis C]]. It is a second-generation protease inhibitor developed by [[Merck & Co.]], and is specifically designed to target the [[NS3/4A]] serine protease of the Hepatitis C virus.<br />
<br />
== Mechanism of Action ==<br />
<br />
Vaniprevir works by inhibiting the NS3/4A serine protease, an enzyme that the Hepatitis C virus requires for replication. By blocking this enzyme, Vaniprevir prevents the virus from replicating within the host's liver cells.<br />
<br />
== Clinical Trials ==<br />
<br />
Vaniprevir has undergone Phase II and Phase III [[clinical trials]] for the treatment of Hepatitis C. In these trials, it has shown significant efficacy in reducing viral load, particularly in patients with genotype 1 Hepatitis C, which is the most common form of the virus in the United States and Europe.<br />
<br />
== Side Effects ==<br />
<br />
Common side effects of Vaniprevir include fatigue, headache, nausea, and diarrhea. In rare cases, it can cause severe skin reactions and liver damage.<br />
<br />
== Regulatory Status ==<br />
<br />
As of 2021, Vaniprevir is approved for use in Japan, but not in the United States or Europe. In Japan, it is marketed under the brand name [[MK-7009]].<br />
<br />
== See Also ==<br />
<br />
* [[Protease inhibitor (pharmacology)]]<br />
* [[Hepatitis C]]<br />
* [[Clinical trial]]<br />
* [[Merck & Co.]]<br />
<br />
[[Category:Protease inhibitors]]<br />
[[Category:Hepatitis C]]<br />
[[Category:Pharmacology]]<br />
{{Pharmacology-stub}}<br />
{{Hepatitis C}}<br />
{{Merck & Co.}}</div>Prab